Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature

Bibliography

• Collaboration ATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
   PubMedGoogle Scholar
• Lohse N, Hansen AB, Pedersen G, Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Thiebaut R, Reiss P, Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491-501
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Furrer H, Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010;170:57-65
   PubMed Web of Science ®Google Scholar
• Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009;11:30-8
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1–239. Section Table K-25. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [as accessed July 23rd, 2012]
   Google Scholar
• EACS. Available from: www.europeanaidsclinicalsociety.org/guidelines.asp 2009
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, Atazanavir plus ritonavir or saquinavir, and lopi navir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Milinkovic A, Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009;51:29-36
   PubMed Web of Science ®Google Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-92
   PubMed Web of Science ®Google Scholar
• Taburet AM, Piketty C, Chazallon C, Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:2091-6
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcia-Gasco P, Vispo E, Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008;61:200-5
   PubMed Web of Science ®Google Scholar
• Jansen K, Sonnerborg A, Pugliese P, Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients [abstract P31]. Tenth International Congres on Drug Therapy in HIV Infection; Glasgow, UK; 2010
   Google Scholar
• Calza L, Manfredi R, Colangeli V, Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS 2009;23:691-7
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Andrade-Villanueva J, Girard PM, A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012;17:689-700
   PubMedGoogle Scholar
• Macassa E, Delaugerre C, Teglas JP, Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J 2006;25:809-14
   PubMed Web of Science ®Google Scholar
• Rubio R, Serrano O, Carmena J, Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Med 2010;11:545-53
   PubMed Web of Science ®Google Scholar
• Sension M, Andrade Neto JL, Grinsztejn B, Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009;51:153-62
   PubMed Web of Science ®Google Scholar
• van Vonderen MG, Gras L, Wit F, Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. HIV Clin Trials 2009;10:168-80
   PubMed Web of Science ®Google Scholar
• Haerter G, Manfras BJ, Mueller M, Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004;18:952-5
   PubMed Web of Science ®Google Scholar
• Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-80
   PubMed Web of Science ®Google Scholar
• Nguyen ST, Eaton SA, Bain AM, Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy 2008;28:323-30
   PubMed Web of Science ®Google Scholar
• Stanley TL, Joy T, Hadigan CM, Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009;23:1349-57
   PubMed Web of Science ®Google Scholar
• Winston A, Mallon PW, Satchell C, The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin Infect Dis 2007;44:1475-83
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-18
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201
   PubMed Web of Science ®Google Scholar
• Carr A, Ritzhaupt A, Zhang W, Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 2008;22:2313-21
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18
   PubMed Web of Science ®Google Scholar
• Ferrer E, del Rio L, Martinez E, Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retroviruses 2011;27:1061-5
   PubMed Web of Science ®Google Scholar
• Zhang D, Chando TJ, Everett DW, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-39
   PubMed Web of Science ®Google Scholar
• Korenblat KM, Berk PD. Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol 2005;3:303-10
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Antinori A, Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009;37:244-9
   PubMed Web of Science ®Google Scholar
• McDonald C, Uy J, Hu W, Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012;26:259-64
   PubMedGoogle Scholar
• Guffanti M, Caumo A, Galli L, Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007;156:503-9
   PubMed Web of Science ®Google Scholar
• Busti AJ, Bedimo R, Margolis DM, Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008;56:539-44
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, d'Ettorre G, Altavilla F, Switching to boosted or unboosted ataza-navir improves glucose tolerance in HIV infected subjects: results from ataglu cohort study [PE9.2/4]. 13th European AIDS Conference (EACS); 12 – 15 October 2011; Belgrade, Serbia
   Google Scholar
• Flammer AJ, Vo NT, Ledergerber B, Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart 2009;95:385-90
   PubMed Web of Science ®Google Scholar
• Colafigli M, Di Giambenedetto S, Bracciale L, Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med 2008;9:172-9
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, Dejesus E, Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010;24:2019-27
   PubMed Web of Science ®Google Scholar
• Squires K, Young B, DeJesus E, Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivu dine (ABC/3TC), after initial suppression with ABC/3TC + ATV/RTV in HIV-1 infected patients: final (144 weeks) results [abstract MOPE215]. 6th IAS Conference on HIV Pathogenesis and Treatment. July 17-20, 2011; Rome, Italy. Poster MOPE215
   Google Scholar
• Ghosn J, Carosi G, Moreno S, Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010;15:993-1002
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Morello J, Barreiro P, Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses 2008;24:821-5
   PubMed Web of Science ®Google Scholar
• Pavie J, Porcher R, Torti C, Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011;66(10):2372-8
   PubMedGoogle Scholar
• Swindells S, DiRienzo AG, Wilkin T, Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006;296:806-14
   PubMed Web of Science ®Google Scholar
• Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007;44:417-22
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pulido F. Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007;46:118-19
   PubMedGoogle Scholar
• Vernazza P, Daneel S, Schiffer V, The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007;21:1309-15
   PubMed Web of Science ®Google Scholar
• Pulido F, Serrano O, Rivero A, Atazanavir/ritonavir monotherapy for maintenan ce of virologic supression: 48-week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study [abstract P4/6]. 12th EACS; 2009. Abstract PS4/6, 12th EACS 2009, Cologne/Germany
   Google Scholar
• Arribas JR, Delgado R, Arranz A, Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009;51:147-52
   PubMed Web of Science ®Google Scholar
• Arribas JR, Horban A, Gerstoft J, The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-30
   PubMed Web of Science ®Google Scholar
• Mills A, Mildvan D, Podzamczer D, Once-daily maraviroc in combination with ritonavir-boosted atazanavir in treatment-naive patients infected with CCR5-tropic HIV-1 (study A4001078): 96-week results[abstract TUAB0102]. XIX International AIDS Conference (AIDS 2012); 22 – 27 July 2012; Washington, DC
   Google Scholar
• Reynes J, Lawal A, Pulido F, Examination of noninferiority, safety, and tolerabili ty of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV Clin Trials 2011;12:255-67
   PubMed Web of Science ®Google Scholar
• Taiwo B, Zheng L, Gallien S, Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25:2113-22
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Pol S, Cooper S, Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV coinfected patients: End of treatment (Week 48) interim results [abstract 47]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 5 - 8 March 2012; Seattle, WA
   Google Scholar
• Hulskotte E, Feng H-P, Xuan F, Pharmacokinetic interaction between the HCV protease inhibitor bocepravir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir [abstract 771-LB]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 5 – 8 March 2012; Seattle, WA
   Google Scholar
• Food and Drug Administration, Victrelis (package insert). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf [As accessed by July 23rd 2012]
   Google Scholar
• Dieterich D, Soriano V, Sherman K, Telaprevir in combination with peginterferion a-2a + ribavirin in HCV/HIVcoinfected patients: a 24-week treatment interim analysis [abstract 46]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 5 – 8 March 2012; Seattle, WA
   Google Scholar
• van Heeswijk R, Vandevoorde A, Boogaerts G, Pharmacokinetic interaction between antiretroviral agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 119]. 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27 – March 2 2011; Boston MA
   Google Scholar
• Food and Drug Administration, INCIVEK (package insert). Accessed July 23, 2012
   Google Scholar
• Thomas DL, Bartlett JG, Peters MG, Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clinical Infectious Disesases 2012;54:979-83
   PubMedGoogle Scholar
• Riddler SA, Haubrich R, DiRienzo AG, Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106
   PubMed Web of Science ®Google Scholar
• Shlay JC, Bartsch G, Peng G, Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007;44:506-17
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011;154:445-56
   PubMed Web of Science ®Google Scholar
• Cahn P, Fourie J, Grinsztejn B, Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011;25:929-39
   PubMed Web of Science ®Google Scholar
• Schrijvers R, Debyser Z. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert Opin Pharmacother 2012;13:1969-83
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012. 379:2429-38
   Google Scholar
• Gallant J, Koenig E, Andrade-Villanueva J, Cobicistat versus ritonavir as pharmacoenhan cers in combination with atazanavir plus tenofovir disoproxil fumarate emtricitabine: phase 3 randomized, double blind, active-controlled trial, week 48 results [abstract TUAB0103]. Program and abstracts of the XIX International AIDS Conference; 22 – 27 July 2012; Washington, DC
   Google Scholar